// App-Quantinova.ai

1503 : Safety of multiplex gene testing for inherited cancer risk: Interim analysis of a clinical trial.

Researchers

Presenter

  • Allison W. Kurian

Principal Investigators

  • Julie Culver

  • Charite Nicolette Ricker

  • Rachel Koff

  • Duveen Sturgeon

  • Katrina Lowstuter

  • Anne-Renee Hartman

  • Brian Allen

  • John Kidd

  • Courtney Rowe-Teeter

  • Kerry Kingham

  • Nicolette M. Chun

  • Iva Petrovchich

  • Meredith Mills

  • Christine Hong

  • Kevin McDonnell

  • Uri Ladabaum

  • James M. Ford

  • Stephen B. Gruber

Medical Centers

  • Stanford University Cancer Institute, Stanford, CA

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Myriad Genetics, Inc., Salt Lake City, UT

  • Keck School of Medicine of USC, Los Angeles, CA

Locations

  • United States

Companies

  • Myriad Genetics, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Adenomatous Polyposis Coli

  • Mismatch repair endonuclease PMS2

  • MutL Homolog 1

  • MutS Homolog 6

  • MutS protein homolog 2

  • mutY DNA glycosylase

  • Nibrin

  • Bone morphogenetic protein receptor, type IA

  • BRCA1 associated RING domain 1

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Cadherin 1

  • Phosphatase and tensin homolog

  • checkpoint kinase 2

  • Cyclin Dependent Kinase Inhibitor 2A

  • Cyclin-dependent kinase 4

  • Liver kinase B1

  • Tumor protein p53

  • Partner and localizer of BRCA2

  • RAD51 Paralog C

  • BRCA1 interacting protein

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • TP53

Outcome

  • Unknown

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • NCT02324062

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved